Liberum Capital restated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research report report published on Monday morning. The firm currently has a GBX 4,800 ($61.99) target price on the biopharmaceutical company’s stock.
A number of other research analysts also recently commented on AZN. Deutsche Bank AG raised their target price on shares of AstraZeneca plc from GBX 5,350 ($69.09) to GBX 5,700 ($73.61) and gave the company a buy rating in a research report on Monday, May 15th. HSBC Holdings plc restated a reduce rating and issued a GBX 4,200 ($54.24) price target on shares of AstraZeneca plc in a report on Monday, May 15th. Shore Capital upgraded shares of AstraZeneca plc to a hold rating and set a GBX 4,800 ($61.99) price target on the stock in a report on Tuesday, May 16th. Berenberg Bank raised their price target on shares of AstraZeneca plc from GBX 5,670 ($73.23) to GBX 5,850 ($75.55) and gave the company a buy rating in a report on Wednesday, May 17th. Finally, Jefferies Group LLC set a GBX 4,700 ($60.70) price target on shares of AstraZeneca plc and gave the company a neutral rating in a report on Saturday, May 20th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of GBX 4,963.82 ($64.11).
AstraZeneca plc (LON AZN) opened at 4899.00 on Monday. The company’s market cap is GBX 62.02 billion. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00. The stock has a 50 day moving average of GBX 4,571.40 and a 200 day moving average of GBX 4,878.32.
AstraZeneca plc (LON:AZN) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $1.01. AstraZeneca plc had a net margin of 8.83% and a return on equity of 14.36%. On average, analysts expect that AstraZeneca plc will post $3.75 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “AstraZeneca plc (AZN) Receives “Buy” Rating from Liberum Capital” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://sportsperspectives.com/2017/09/12/astrazeneca-plc-azn-receives-buy-rating-from-liberum-capital.html.
The company also recently announced a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were issued a dividend of GBX 68.90 ($0.89) per share. This represents a dividend yield of 1.35%. The ex-dividend date was Thursday, August 10th.
In other news, insider Nazneen Rahman bought 39 shares of the business’s stock in a transaction dated Thursday, July 27th. The stock was purchased at an average cost of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.